TY - JOUR
T1 - Cellular senescence in the lung across the age spectrum
AU - Parikh, Pavan
AU - Wicher, Sarah
AU - Khandalavala, Karl
AU - Pabelick, Christina M.
AU - Britt, Rodney D.
AU - Prakash, Y. S.
N1 - Funding Information:
This work was supported by the Mayo Clinic Department of Obstetrics and Gynecology (P. Parikh), NIH Grants T32 HL105355 (S. Wicher), R00 HL131682 (R. Britt), R01 HL138402 (C. Pabelick), and R01 HL056470 (Y. S. Prakash), an American Heart Association Postdoctoral Fellowship Award (S. Wicher), and by a pilot grant from the Center for Biomedical Discovery and the Mayo Clinic Center for Clinical and Translational Science (R. Britt and C. Pabelick) NCATS UL1 TR002377.
Publisher Copyright:
© 2019 the American Physiological Society.
PY - 2019/5
Y1 - 2019/5
N2 - Cellular senescence results in cell cycle arrest with secretion of cytokines, chemokines, growth factors, and remodeling proteins (senescence-associated secretory phenotype; SASP) that have autocrine and paracrine effects on the tissue microenvironment. SASP can promote remodeling, inflammation, infectious susceptibility, angiogenesis, and proliferation, while hindering tissue repair and regeneration. While the role of senescence and the contributions of senescent cells are increasingly recognized in the context of aging and a variety of disease states, relatively less is known regarding the portfolio and influences of senescent cells in normal lung growth and aging per se or in the induction or progression of lung diseases across the age spectrum such as bronchopulmonary dysplasia, asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis. In this review, we introduce concepts of cellular senescence, the mechanisms involved in the induction of senescence, and the SASP portfolio that are relevant to lung cells, presenting the potential contribution of senescent cells and SASP to inflammation, hypercontractility, and remodeling/fibrosis: aspects critical to a range of lung diseases. The potential to blunt lung disease by targeting senescent cells using a novel class of drugs (senolytics) is discussed. Potential areas for future research on cellular senescence in the lung are identified.
AB - Cellular senescence results in cell cycle arrest with secretion of cytokines, chemokines, growth factors, and remodeling proteins (senescence-associated secretory phenotype; SASP) that have autocrine and paracrine effects on the tissue microenvironment. SASP can promote remodeling, inflammation, infectious susceptibility, angiogenesis, and proliferation, while hindering tissue repair and regeneration. While the role of senescence and the contributions of senescent cells are increasingly recognized in the context of aging and a variety of disease states, relatively less is known regarding the portfolio and influences of senescent cells in normal lung growth and aging per se or in the induction or progression of lung diseases across the age spectrum such as bronchopulmonary dysplasia, asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis. In this review, we introduce concepts of cellular senescence, the mechanisms involved in the induction of senescence, and the SASP portfolio that are relevant to lung cells, presenting the potential contribution of senescent cells and SASP to inflammation, hypercontractility, and remodeling/fibrosis: aspects critical to a range of lung diseases. The potential to blunt lung disease by targeting senescent cells using a novel class of drugs (senolytics) is discussed. Potential areas for future research on cellular senescence in the lung are identified.
KW - Aging
KW - Airway
KW - Alveoli
KW - Bronchi
KW - Senolytic
UR - http://www.scopus.com/inward/record.url?scp=85065540322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065540322&partnerID=8YFLogxK
U2 - 10.1152/ajplung.00424.2018
DO - 10.1152/ajplung.00424.2018
M3 - Review article
C2 - 30785345
AN - SCOPUS:85065540322
SN - 1040-0605
VL - 316
SP - L826-L842
JO - American Journal of Physiology
JF - American Journal of Physiology
IS - 5
ER -